Safety Assessment on Isolated Cannabidiol (CBD) as a Novel Food for Use in Food Supplements (RP427)

Author:

,

Abstract

An application was submitted to the Food Standards Agency (FSA) and Food Standards Scotland (FSS) in February 2021 from EIHA Projects GmbH (“the applicant”) for the authorisation of isolated cannabidiol (CBD) as described in RP427, as a novel food. This is a joint application from EIHA associated product partners pertaining to a novel food which is to be prepared and used according to the specification set out within this document. It must be noted that any authorisation subsequent to this application pertains solely to the novel food and not to any proposed uses as an ingredient in any other products. The novel food is a >98% pure, hemp-derived CBD isolate which is intended to be used in hemp oil as a food supplement for adults. For CBD a provisional Acceptable Daily Intake (ADI) of 10 mg/day for a healthy 70kg adult has been published by the FSA and was considered in assessing this novel food. The provisional ADI (section 2.7) was recommended, subject to the existing advice that certain populations do not consume CBD, due to remaining data gaps and residual uncertainties concerning the safety of CBD for these groups of consumers. These contraindications would also apply to this novel food. To support the FSA and FSS in their evaluation of the application, the Advisory Committee on Novel Foods and Processes (ACNFP) were asked to review the safety dossier and supplementary information provided by the applicant. The Committee did not consider any potential health benefits or claims arising from consuming the food, as the focus of the novel food assessment is to ensure the food is safe, and not putting consumers at a nutritional disadvantage. The Committee concluded that the applicant had provided sufficient information to assure the novel food, an isolated CBD as detailed in application RP427, was safe under the proposed conditions of use. The anticipated intake levels and the proposed use in food supplements was not considered to be nutritionally disadvantageous.

Publisher

Food Standards Agency

Reference35 articles.

1. Joint position paper from the Advisory Committee on Novel Foods and Processes (ACNFP) & Committee on Toxicity (COT) on establishing a provisional acceptable daily intake (ADI) for pure form (≥98%) cannabidiol (CBD) in foods, based on new evidence;Advisory Committee on Novel Foods and Processes (ACNFP),2023

2. Committee On Mutagenicity Of Chemicals In Food, Consumer Products And The Environment, (MUT/MIN/2020/1), 2020; https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/967784/Final_COM_mins_February_2020.pdf#:~:text=The%20Committee%20on%20the%20Toxicity%20of%20Chemicals%20in,requested%20a%20COM%20view%20of%20the%20genotoxicity%20data.

3. de Jong BG, 2020 [unpublished]. Prepared by Charles River Laboratories Den Bosch B.V., DD ‘s Hertogenbosch, The Netherlands for Chanelle McCoy CBD Ltd., Loughrea, Galway, Ireland. Study Title: Cannabidiol: in vitro mammalian cell micronucleus test. Confidential. (Test Facility Study No. 20203946).

4. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome [GWPCARE1 Part A Study Group];O. Devinsky;Neurology,2018

5. Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements;OJ L 183,2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3